Hormone therapy may be safe to treat menopausal symptoms in women who suffer from migraines, a study has affirmed.
Migraine is a headache of varying intensity, often accompanied by nausea and sensitivity to light and sound.
Hormones have often not been prescribed for migraine sufferers because of the association between exogenous oestrogen use and an increased risk of stroke in women who have migraines.
This led to the recommendation that combined oral contraceptives (better known as birth control pills) should be used cautiously or avoided entirely in women with a history of migraines, depending on whether or not the migraines were accompanied by an aura.
However, the study "brought further clarity to its safe use, especially in younger women (below 60) who are closer to the time of menopause (within 10 years of menopause)," said Peter F. Schnatz, from Thomas Jefferson University in the US.
"Since migraines affect one in every four women and they are often advised to avoid hormone therapy, the new findings may have significant public health implications," added Jelena Pavlovic, from Albert Einstein College of Medicine in the New York, while presenting the findings during the North American Menopause Society (NAMS) Annual Meeting in Philadelphia.
For the study, the team analysed data for 67,903 participants to examine the relationship between migraines and cardiovascular disease events and their interaction with hormone therapy use.
It was discovered that women with migraines tend to drink and exercise less than those without migraines.
Importantly, researchers did not detect a significant risk of cardiovascular disease events associated with a history of migraines. Most significantly, from the treatment safety perspective, there was no impact from hormone therapy on this relationship.
--IANS
rt/in
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
